CTOs on the Move

Mylan

www.mylan.com

 
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.mylan.com
  • 1000 Mylan Boulevard
    Canonsburg, PA USA 15317
  • Phone: 724.514.1800

Executives

Name Title Contact Details
Matthew Smith
 Global Executive Director - Cyber and Information Security Profile
Ramkumar Rayapureddy
 Global Chief Information Officer Profile
Franklin Donahoe
 Chief Information Security Officer Profile
Franklin Donahoe
 Chief Information Security Officer Profile

Similar Companies

SunMed

Select SunMed for Anesthesia and Respiratory Care SolutionsDedicated to Improving Quality of LifeWho Is SunMedSelect SunMed for Your Place to GrowDedicated to Improving Quality of LifeCareers with SunMedSelect SunMed for Medical Device ManufacturingDed...

Coastal Medical

Coastal Medical, Inc. is Rhode Islands largest, physician owned and physician governed Primary Care practice, serving patients in RI and southeastern Massachusetts.

Dyancon

Dyancon is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atlantic Biologicals Corporation

Atlantic Biologicals Corporation is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.